US2021220487A1PendingUtilityA1
Intrathecal delivery of recombinant adeno-associated virus 9
Assignee: NATIONWIDE CHILDRENS HOSPITALPriority: Aug 1, 2012Filed: Mar 9, 2021Published: Jul 22, 2021
Est. expiryAug 1, 2032(~6.1 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 21/04C07K 14/47C12N 2750/14143A61K 38/1709A61P 25/28A61K 48/0075A61K 48/0008C12N 15/86A61P 25/00A61K 48/00A61P 21/00A61P 25/02C07H 21/04A61K 49/0438
76
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-osmolar contrast agent, together with a rAAV9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone.
Claims
exact text as granted — not AI-modified1 . A method of treating a CLN2 disease in a patient in need thereof, comprising delivering intrathecally to the patient a composition comprising a combination of a recombinant AAV9 (rAAV9) and a non-ionic, low-osmolar contrast agent, wherein the rAAV9 comprises an rAAV9 genome comprising a CLN2 gene.
2 . The method according to claim 1 , wherein the rAAV9 genome is a self-complementary genome.
3 . The method of claim 1 , wherein the rAAV9 genome is a single-stranded genome.
4 . The method of claim 1 , wherein the non-ionic, low-osmolar contrast agent is iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, ioversol, ioxilan, or a combination thereof.
5 . The method according to claim 1 , wherein the non-ionic, low-osmolar contrast agent is iohexol.
6 . The method of claim 1 , wherein the composition is formed by mixing the rAAV9 and the non-ionic, low-osmolar contrast agent prior to delivering intrathecally to the patient.
7 . The method of claim 1 , wherein the combination is delivered as sequential administrations.
8 . The method of claim 1 , wherein delivering intrathecally comprises delivery into the space under the arachnoid membrane of the brain or spinal cord.
9 . The method according to claim 1 wherein the patient is a human.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.